Health Trials

Viral Hepatitis

3

Review clinical trials related to Viral Hepatitis. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.

Participants needed: 140
Trial details
Phase: Phase 4Age: 20+Biological sex: AllType: InterventionalSponsor: Taichung Veterans General HospitalUpdated: May 14, 2026Locations: 1
Eligibility criteria

Patients more than 20 years old [+2]

Decompensated liver disease (Child-Pugh B &C) [+7]

Read more
Status: Recruiting

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide

Participants needed: 150
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Vir Biotechnology, Inc.Updated: May 6, 2026Locations: 38
Eligibility criteria

Male or female ages 18 to 70 years at screening [+4]

Serum ALT ≥ 5 × ULN [+7]

Read more
Status: Recruiting

Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures "Outside the Walls" by Dual Screening Method RTDs and FibroScan®

The "Scanvir" concept aims to achieve barriers to HCV screening and treating of marginalized patients. The concept is applicable to other various populations and territories and should effectively improve HCV patient's health outcomes. The main objective of the SCANVIR project was to evaluate the feasibility, acceptability and reproducibility of a "test, treat and cure" strategy for PWIDs and vulnerable populations during dedicated days in addiction care centers.

Participants needed: 2,300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: University Hospital, LimogesUpdated: Aug 14, 2025Locations: 1Duration: 1 Day
Eligibility criteria

Adult 18 and over [+2]

Age under 18 [+1]

Read more